Gradientech appoints Sumi Thaker as Chief Executive Officer to lead its next phase of commercial growth
The new CEO Sumi Thaker brings over 30 years of experience at UCB, bioMérieux, and Thermo Fisher
Gradientech, a diagnostics company pioneering ultra-rapid antibiotic susceptibility testing, today announces the appointment of Sumi Thaker as Chief Executive Officer, with effective date 1 August 2026. Sumi will lead the company’s next phase of growth as Gradientech accelerates the global commercialisation of QuickMIC.
Sumi succeeds Sara Thorslund, who co-founded Gradientech and led its development since 2009, taking the company from an early-stage research idea to a clinically validated diagnostic platform. The appointment marks a deliberate move into the company’s next chapter, as Gradientech shifts its focus from technology development towards commercial execution and international market expansion.
Sumi brings more than three decades of international leadership across the pharmaceutical and diagnostics sectors. He has held senior commercial, marketing and executive positions at leading global companies including UCB, bioMérieux and Thermo Fisher Scientific, with responsibilities spanning international markets, brand strategy and business growth, having begun his career at Sanofi. Most recently, he served as Chief Executive Officer and Commercial Director at Momentum Bioscience, where he led the development of innovative diagnostic technologies.
“I am honoured to take on the role of CEO at such an important stage in the company’s development,” says Sumi Thaker, CEO of Gradientech. “Sara Thorslund and the team have created a clinically proven technology that directly addresses antibiotic resistance, one of the defining health challenges of our time. My focus now is to build on that foundation — scaling our commercial organisation, deepening our customer and partner relationships, and realising the full potential of QuickMIC® for patients and healthcare systems worldwide.”
“On behalf of the Board, I want to thank Sara Thorslund for her dedication in building Gradientech over many years,” says Gisela Sitbon, Chair of the Board. “As Gradientech moves into a growth and commercialisation phase, Sumi brings exactly the international commercial leadership the company needs. His proven track record of driving commercial success and strategic growth in diagnostics makes him the right person to expand market adoption and create long-term value for patients, customers and shareholders.”
Original publication
.
Other news from the department people
These products might interest you
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.